Posted by Michael Wonder on 10 Sep 2022
US Food and Drug Administration approves Sotyktu (deucravacitinib), oral treatment for adults with moderate to severe plaque psoriasis
9 September 2022 - Bristol Myers Squibb’s Sotyktu, a first in class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is the only approved TYK2 inhibitor worldwide and the first innovation in oral treatment for moderate to severe plaque psoriasis in nearly 10 years.
Bristol Myers Squibb today announced that the U.S. FDA approved Sotyktu (deucravacitinib), a first in class, oral, selective, allosteric tyrosine kinase 2 inhibitor, for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
